Dr Tina Caroline Flatau
About Dr Tina Caroline Flatau
Dr. Tina Caroline Flatau is a seasoned biopharmaceutical executive with over twenty years of experience, currently serving as the Chief Business Officer and holding a PhD in pharmaceutical sciences.
Dr Tina Flatau's Role as Chief Business Officer
Dr Tina Caroline Flatau currently serves as the Chief Business Officer. In this role, she is responsible for managing business operations and strategic planning. Her extensive experience in biopharmaceuticals spans over twenty years, making her a valuable asset to the companies she engages with. Dr Flatau's work involves shaping business strategies, overseeing collaborations, and driving operational growth within the pharmaceutical sector.
Dr Tina Flatau's Education and Expertise
Dr Tina Flatau holds a PhD in pharmaceutical sciences, a credential that underscores her deep understanding of the field. Her expertise is further demonstrated through her varied roles and contributions to the biopharmaceutical industry. With two decades of experience, she has gained comprehensive knowledge across the R&D spectrum, working with multinational corporations to innovative start-ups in the USA, EU, and UK.
Dr Tina Flatau's Background in Biopharmaceuticals
Dr Tina Flatau has a rich background in the biopharmaceutical industry. She was previously a Principal in PwC’s Pharmaceutical Industry Group and has significant experience managing pharmaceutical collaborations and operational growth. At Prosensa Therapeutics, she oversaw a successful IPO on NASDAQ, highlighting her capability in managing business-side SEC aspects. Her operational and strategic insights have contributed to the growth and success of various biopharmaceutical ventures.
Dr Tina Flatau's Contributions to Oncology Therapy
In the field of oncology, Dr Tina Flatau has made significant contributions through her work on T-cell modulation approaches. She is the author of patents for these innovative therapies, which have reached clinical Phase II trials in the UK. These contributions highlight her role in advancing cancer treatment and her commitment to developing breakthrough therapies.
Dr Tina Flatau's Leadership in Biotech Development
Dr Tina Flatau has played a pivotal role in building biotechs such as MedAnnex Ltd and aTen Therapeutics Ltd. At MedAnnex, the company secured an £11 million funding round in 2019, showcasing her capability in securing investment and driving biotech growth. Both companies are focused on developing monoclonal antibodies for annexin-A1 and angiotensin II modulation, underlining her expertise in fostering innovation within the biotech sector.
Dr Tina Flatau's Involvement with Action Duchenne
Dr Tina Flatau has been actively involved with the rare disease charity Action Duchenne, where she has served as a board member and previously held the position of Chair. Her work with the charity reflects her commitment to advocating for rare disease research and support, further demonstrating her dedication to making an impact beyond the commercial biopharmaceutical realm.
Dr Tina Flatau's Role in NHS Health Research Authority
In addition to her industry roles, Dr Tina Flatau is a member of the NHS Health Research Authority Research Ethic Committee. This position involves reviewing and approving research proposals to ensure they adhere to ethical standards, emphasizing her commitment to maintaining integrity and ethical considerations in medical research.